Emily L. Gramiccioni

Sysmex (Japan)

Papers

1

Total Citations

7

H-Index

1

About

Emily L. Gramiccioni is a leading oncologist and translational researcher whose work focuses on refining treatment paradigms for human papillomavirus-associated (HPV+) oropharyngeal cancer. Her major contributions center on leveraging circulating tumor HPV DNA (ctHPV-DNA) as a dynamic biomarker to guide response-adapted de-escalation of chemotherapy, aiming to reduce treatment toxicity without compromising excellent survival outcomes. Her most-cited paper, “Early Dynamics of Circulating Tumor HPV-DNA with Neoadjuvant Chemotherapy and Response-Adapted De-escalation in Human Papillomavirus–Associated Oropharyngeal Cancer” (2025, 7 citations), demonstrates how early ctHPV-DNA kinetics can identify patients who may safely receive less intensive therapy. This work is notable for its potential to shift clinical practice toward more personalized, less toxic regimens in a disease where overtreatment remains a significant concern. Dr. Gramiccioni’s research sits at the intersection of precision oncology and biomarker-driven care, offering a promising path to improve quality of life for patients with HPV+ oropharyngeal cancer. Her emerging citation record underscores the growing interest in her innovative, patient-centered approach to de-escalation strategies.

Research Focus

Key Achievements

1
H-Index
1
Papers
7
Total Citations
7
Avg Citations/Paper
🏆 Most Cited Paper
Early Dynamics of Circulating Tumor HPV-DNA with Neoadjuvant Chemotherapy and Response-Adapted De-escalation in Human Papillomavirus–Associated Oropharyngeal Cancer
7 citations · 2025
📈 Most Prolific Year: 2025 (1 Papers)
🤝 Key Collaborators: 18
🏛 Institutions: Sysmex (Japan)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago